ArticleInternational journal of vascular medicine2012
Restenosis and therapy.
Article in International journal of vascular medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Development and validation of a nomogram for in-stent restenosis within 2 years in patients after iliac or femoral artery stent placement.BMC surgery · 2025Article
- Effect of Peri-Interventional Blood Loss on In-Stent Thrombosis After Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction.Journal of cardiovascular development and disease · 2025Article
- Degraded products generated by iron stent inhibit the vascular smooth muscle cell proliferation by downregulating AP-1.Journal of materials science. Materials in medicine · 2025Article
- A Spotlight on PLGA-based Nanoparticles: Pioneering a New Era in the Therapeutics of Cardiovascular Disorders.Current pharmaceutical design · 2025Review
- Pathogenesis and Clinical Significance of In-Stent Restenosis in Patients with Diabetes.International journal of environmental research and public health · 2021Review
- TiOACS biomaterials science & engineering · 2020Article
- Regulation of Stress Granule Formation by Inflammation, Vascular Injury, and Atherosclerosis.Arteriosclerosis, thrombosis, and vascular biology · 2019Article
- The effect of Telmisartan on the expression of connexin43 and neointimal hyperplasia in a rabbit iliac artery restenosis model.Heart and vessels · 2019Article
- Id-1 Promotes Reendothelialization In The Early Phase After Vascular Injury Through Activation Of NFkB/survivin Signaling Pathway.Drug design, development and therapy · 2019Article
- Heme oxygenase-1 (HO-1) alleviates vascular restenosis after balloon injury in a rabbit carotid artery model.International journal of clinical and experimental pathology · 2018Article
- Vitronectin and Urokinase-Type Plasminogen Activator Gene Expression Levels Are Increased in Patients with Coronary Artery In-Stent Restenosis.The International journal of angiology : official publication of the International College of Angiology, Inc · 2017Article
- ERK signaling is required for VEGF-A/VEGFR2-induced differentiation of porcine adipose-derived mesenchymal stem cells into endothelial cells.Stem cell research & therapy · 2017Article
- Diagnostic value of microRNA-143 in predicting in-stent restenosis for patients with lower extremity arterial occlusive disease.European journal of medical research · 2017Article
- ON VASCULAR STENOSIS, RESTENOSIS AND MANNOSE BINDING LECTIN.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2016Review
- Nanostructured ultra-thin patches for ultrasound-modulated delivery of anti-restenotic drug.International journal of nanomedicine · 2016Article
- Synergistic effect of a tissue kallikrein 1 and tissue inhibitor of matrix metalloproteinase 1 co‑expression vector on the proliferation of rat vascular smooth muscle cells.Molecular medicine reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The vascular disease involves imbalanced function of the blood vessels. Risk factors playing a role in development of impaired vessel functions will be briefly discussed. In ischemia/reperfusion (I/R), ischemic hypoxia is one of the cardinal risk factors of restenosis. Various insults are shown to initiate the phenotype switch of VSMCs. The pathological process, leading to activated inflammatory process, complement activation, and release of growth factors, initiate the proliferation of VSMCs in the media and cause luminal narrowing and impaired vascular function. The review summarizes the alteration process and demonstrates some of the clinical genetic background showing the role of complement and the genotypes of mannose-binding lectin (MBL2). Those could be useful markers of carotid restenosis after stent implantation. Gene therapy and therapeutic angiogenesis is proposed for therapy in restenosis. We suggest a drug candidate (iroxanadine), which ensures a noninvasive treatment by reverse regulation of the highly proliferating VSMCs and the disturbed function of ECs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.